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COGNITIVE ASSESSMENT OF OLDER PEOPLE
Routine test batteries for cognitive impairment in older
people may not be cost effective
Michael Marks core medical trainee
St Thomas’ Hospital, London SE1 7EH, UK
Young and colleagues provide guidance on assessing cognitive
impairment in older people, including the use of a battery of
tests to establish the underlying cause.1 The value of such
exhaustive test batteries, however, is not well validated.
Brodaty tested consecutive patients attending a memory
disorders clinic.2 No patient had “significant relevant
abnormalities” identified. Equivocal abnormalities of low
vitamin B12, folate, and thyroid function were each identified
once in 13 patients. In no patients did treatment affect the course
of cognitive decline. Computed tomography and
electroencephalography seemed to have greater yield. Siu also
found that, in the absence of evidence of deficiency, the yield
of measuring vitamin B12 in patients with a normal full blood
count was minimal.3 VDRL testing was also of minimal value.
Another study found blood counts, thyroid function, calcium,
and glucose valuable in assessing patients with dementia.4
Unselected vitamin B12 testing cost $6426 (£4117; €4752) per
diagnosis of vitamin B12 deficiency. Testing only patients with
abnormal full blood counts reduced this to $2260.42 without
affecting sensitivity. Folate deficiency was seen mainly in
patients with abnormal blood counts; those with normal blood
counts and low folate did not benefit from treatment. They
estimated the cost of using exhaustive test batteries to assess 3
million people at $2.1-3bn, or $450-630 million for more
selective testing.
This highlights the need to consider the yield of each test in the
patient being assessed. Rates of diagnosis are similar for tailored
testing rather than unselected test batteries, but costs are much
lower.
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